(24/7 MARKET NEWS) – We covered Lucira Health’s (Nasdaq: LHDX) FDA emergency use authorization news, on Monday, for its Lucira COVID-19 & Flu Home Test for over the counter use at home and other non-laboratory sites, when Lucira was at $0.503.
It hit a new 2023 high of $1.18, yesterday, and closed at $0.93, up $0.42 (+82.35%), on trading volume of 228,479,141 shares. It’s currently trading at $0.992, up $0.062 (+6.68%), on 3.5 million premarket shares, and hit a premarket high of $1.09.
Its 52-week trading range is $0.108 to $5.67. Its next key inflection points are $1.09, $1.18, and $1.28. If it can break through the $1.28 resistance level, on strong volume, it’s likely going to try to challenge September’s $1.75 trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.